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Abstract
Background: The CONSORT Statement is a reporting guideline for authors when reporting randomized controlled trials
(RCTs). It offers a standard way for authors to prepare RCT reports. It has been endorsed by many high-impact medical
journals and by international editorial groups. This study was conducted to assess the endorsement of the CONSORT
Statement by high-impact medical journals in China by reviewing their instructions for authors.
Methodology/Principal Findings: A total of 200 medical journals were selected according to the Chinese Science and
Technology Journal Citation Reports, 195 of which publish clinical research papers. Their instructions for authors were
reviewed and all texts mentioning the CONSORT Statement or CONSORT extension papers were extracted. Any mention of
the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (URM) developed by the International
Committee of Medical Journal Editors (ICMJE) or ‘clinical trial registration’ was also extracted. For journals endorsing the
CONSORT Statement, their most recently published RCT reports were retrieved and evaluated to assess whether the journals
have followed what the CONSORT Statement required. Out of the 195 medical journals publishing clinical research papers,
only six (6/195, 3.08%) mentioned ‘CONSORT’ in their instructions for authors; out of the 200 medical journals surveyed, only
14 (14/200, 7.00%) mentioned ‘ICMJE’ or ‘URM’ in their instructions for authors, and another five journals stated in their
instructions for authors that clinical trials should have trial registration numbers and that priority would be given to clinical
trials which had been registered. Among the 62 RCT reports published in the six journals endorsing the CONSORT
Statement, 20 (20/62, 32.26%) contained flow diagrams and only three (3/62, 4.84%) provided trial registration information.
Conclusions/Significance: Medical journals in China endorsing either the CONSORT Statement or the ICMJE’s URM
constituted a small percentage of the total; all of these journals used ambiguous language regarding what was expected of
authors.
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Introduction
In 1996, in response to concerns about quality of reporting of
randomised controlled trials (RCTs), an international group
developed the Consolidated Standards of Reporting Trials
(CONSORT) Statement [1]. As a worldwide accepted guideline
for reporting RCTs, the CONSORT Statement has been in use
for 15 years and was updated twice in 2001 and 2010, respectively
[2,3]. The CONSORT Statement, which is an evidence-based,
minimum set of recommendations for reporting RCTs, offers a
standard way for authors to prepare reports of trial findings,
facilitating their complete and transparent reporting, and aiding
their critical appraisal and interpretation [4,5]. CONSORT has
been endorsed by several hundred medical journals, including
many high-impact-factor ones, and by international editorial
groups, such as the International Committee of Medical Journal
Editors (ICMJE). Since the publication of CONSORT, several
studies have been conducted to assess the impact of using the
CONSORT Statement on improving the reporting of RCTs in
medical journal articles [6–8]. The majority of their results
indicated that CONSORT has helped improve the quality of
reporting of RCTs and thus confirm its usefulness.
The ICMJE developed the Uniform Requirements for Manu-
scripts Submitted to Biomedical Journals (URM) primarily to
help authors and editors in their mutual task of creating and
distributing accurate, clear, easily accessible reports of biomedical
studies. The ICMJE states in URM the ethical principles in the
conduct and reporting of research and provides recommendations
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order to urge researchers to conduct research ethically and to
report it honestly, in 2004, the members of the ICMJE published a
joint editorial aimed at promoting registration of all clinical trials
and stated that ICMJE member journals will consider a trial for
publication only if it has been registered before the enrollment of
the first patient [10].
According to the Global Research Report released by Thomson
Reuters in 2009 [11], China produced approximately 400,000
papers in all fields of science in a recent five-year period, accounting
for approximately 8?5% of the world’s papers published in journals
indexed by Thomson Reuters. Thomson Reuters recorded 1,745
papers from China in 1981 but 127,075 in 2009, representing an
astonishing change in world share from 0?4% to 10?9%. China is
now second to the US, the largest single-nation producer, and will
likely surpass the EU27 nations in research paper output in the next
decade [12]. Also, there are over 1,000 medical journals published
in China now and this number is still rising. Although most of them
have not ranked as the world leading journals in their specialties,
some of them have already been adhering to international
conventions.
Since the quality of clinical medical research papers from
Chinese authors has always been a topic of discussion and the
guiding impact of medical journals should not be ignored, it is
necessary to get an overview of the Chinese medical journals’
requirements for their authors. Hence in this study, the
endorsement of the CONSORT Statement by high-impact
medical journals in China in their instructions for authors was
investigated, and any mention of the ICMJE’s URM was also
studied.
Methods
From April 2011 to June 2011, using the 2009 impact factors of
the Chinese Science and Technology Journal Citation Reports
(CSTJCR) released by the Institute of Science and Technical
Information of China [13], the top 20 journals of each of the four
categories including internal medicine, surgery, clinical medicine,
and Chinese medicine and top ten journals of each of the other 12
categories (oncology; healthcare medicine; gynaecology, obstetrics
and pediatrics; nursing; medical imaging; stomatology; neurology
and psychiatry; ophthalmology and otorhinolaryngology; phar-
macy; medical university journals; general medicine; preventive
medicine and hygienics) were selected according to different total
number of each category. A total of 200 high-impact medical
journals were identified and their ‘instructions for authors’ were
downloaded from their websites or copied from the most recently
published issues. Two authors (Li XQ and Tao KM) read these
instructions and extracted text mentioning ‘CONSORT’,
‘ICMJE’, ‘URM’, or ‘trial registration’, independently. A third
author (Zhou QH) was consulted if consensus could not be
reached between the two authors. The texts mentioning the above
words were analyzed to evaluate the strength of their requirements
for authors. By reading these instructions and browsing the
published articles of the last few years in databases or journal
websites, those journals that do not publish clinical trials were
excluded when judging the endorsement of the CONSORT
Statement.
Full-text papers of RCTs published in the most recent issues
(June 2010 to June 2011 for monthly or bimonthly published
journals and January 2011 to June 2011 for those published
semimonthly or weekly) of the journals which mentioned
‘CONSORT’ in their instructions for authors were downloaded.
Two authors (Li XQ and Tao KM) reviewed these RCT reports to
see whether they contained flow diagrams as the CONSORT
Statement required, and whether they provided trial registration
information.
Results
Endorsement of the CONSORT Statement by high-impact
medical journals in China
By reading instructions for authors and by browsing the
published articles in databases or journals’ websites, those journals
that do not publish clinical trials were excluded (n=5). Out of the
remaining 195 journals, only six mentioned ‘CONSORT’ in their
instructions for authors (6/195, 3.08%). Among the six, two gave
references which published the CONSORT Statement (either
English version or Chinese version) as well as web links to the
CONSORT website; these two journals also listed several other
reporting standards such as TREND, PRISMA, etc. Although
some of them are not newly updated, the web links may ensure
accurate reference for their readers or authors. One journal gave a
web link to the CONSORT website and a 22-item checklist of the
2001 version. Two journals stated that authors of RCTs should
provide the CONSORT checklist and a flow chart of the trial.
One recommended authors of RCTs to refer to the CONSORT
Statement. Those journals that did not mention CONSORT
provided no other reporting guidance for authors.
Endorsement of the URM by high-impact medical
journals in China
Out of the 200 journals surveyed, only 14 journals mentioned
‘ICMJE’ or ‘URM’ in their instructions for authors (14/200,
7.00%). They either gave the ICMJE website link, or gave a
reference to a published URM text, or mentioned an exact version
they endorsed, or quoted some texts from the URM, or specially
mentioned trial registration procedures. Apart from these 14
journals, five journals stated in their instructions for authors that
clinical trials should have trial registration numbers and that
priority would be given to clinical trials which had been registered.
RCT reports from the journals endorsing the CONSORT
Statement
A total of 62 RCT reports were collected from the six journals
endorsing the CONSORT Statement. They were all published in
the most recent issues. Among these RCT reports, 20 (20/62,
32.26%) contained flow diagrams and only three (3/62, 4.84%)
provided trial registration information (Table 1).
Discussion
The CSTJCR is the most authoritative citation reports in
China, which is released by the Institute of Science and Technical
Information of China and updated once a year [13]. Journals
indexed in this citation report are called ‘core journals’ and have
achieved a good reputation in China. Chinese authors consistently
select these journals for publication of their research papers as well
as degree papers. In this study, 200 core journals were selected
from 16 medical specialty categories in the 2009 citation reports
for investigating the endorsement of the CONSORT Statement
and the URM by these high-impact medical journals in China.
There are only six journals that mentioned ‘CONSORT’ in their
instructions for authors and the number of journals that
mentioned the ICMJE or the URM is slightly more at 14; both
constitute a small percentage of the total. The two proportions are
much lower than those reported in Altman’s study which selected
journals indexed in the Science Citation Index (SCI) [6]. Five
Endorsement of CONSORT by Chinese Medical Journals
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clinical trials should have trial registration numbers and priority
will be given to clinical trials which had been registered. However,
all journals endorsing either the CONSORT Statement or the
URM used ambiguous language regarding what was expected of
authors.
RCT reports published in the most recent issues of journals
that endorsed the CONSORT Statement were reviewed. As
the participant flow diagram is strongly recommended in the
CONSORT 2010 Statement [3], we chose the flow diagram as
the standard to assess whether the journal had followed the
CONSORT Statement requirements. By reviewing the 62
published RCTs in the six journals endorsing the CONSORT
Statement, only one third (20/62, 32.26%) provided flow diagrams.
It could be speculated that inclusion of flow diagrams in RCT
papers was dependent on whether the authors have provided one.
Only the Journal of Chinese Integrative Medicine is an exception as each
of the ten RCTs published in its past one year issues included a flow
diagram. For some randomized trials the flow of participants
through each phase of the trial can be relatively straightforward to
describe, particularly where there were no losses to follow-up or
exclusions. However, in more complex trials it may be difficult for
readers to discern whether and why some participants did not
receive the treatment as allocated, were lost to follow-up, or were
excluded from the analysis [14]. A completed flow diagram is
especially valuable for such trials. A complete CONSORT flow
diagram reduces the time taken for readers to find the essential
information to assess the reliability of a trial. It is also likely to
improve the availability of some information which otherwise might
not be reported. Poor reporting of participant eligibility makes it
difficult to know whether the enrolment process was highly selective
and whether those who enrolled were representative of the general
population [15,16].
‘Trial registration number and name of trial registry’ is a new
item added in the CONSORT 2010 checklist as empirical
evidence supports the need for trial registration, and requirements
by ICMJE in 2004 have fostered compliance [3,10]. So whether
trial registration information is incorporated in these published
RCTs was also judged as a standard. Only three RCT papers
provided trial registration information, which were all published
in the Chinese Medical Journal (English version), taking a small
percentage of all its published RCTs between January 2011 to
June 2011 (3/23, 13.04%).
Among the 200 Chinese medical journals, four journals are
indexed in the SCI or SCI-E. However, among these four
journals, only one journal endorsed the CONSORT Statement
and only two journals gave a web link to the ICMJE website. The
SCI journals are deemed as representative of high-quality and
high-impact journals; nevertheless, the endorsement of the
CONSORT Statement or the URM by these Chinese SCI
journals is not encouraging. Also, by reviewing the instructions for
authors of the series journals of the Chinese Medical Association,
which are regarded as the high-quality standard for Chinese
medical journals, none of them except the Chinese Medical Journal
(English version) mentioned the CONSORT Statement or gave a
web link to the ICMJE website.
The CONSORT Statement and the URM as well as their
revised or updated versions have already been translated into
Chinese and published in some Chinese medical journals [17–25].
Therefore it is assumed that journal editors as well as authors in
China could have easy access to the CONSORT Statement and
the URM which are easily intelligible to them. It is noteworthy to
mention that those journals that lack CONSORT did not use any
alternative guideline to the CONSORT Statement, namely, they
simply lack guidelines.
A number of clinical research papers are published in China
each year; however, according to several studies evaluating the
quality of reporting of RCTs conducted in China, none of them
achieved positive results [26–28]. When looking back to the
vehicle of these papers, as what is indicated in this study, we may
see why the quality of clinical research papers in China lag behind
so far from the international standard. The reasons that so few
medical journals in China endorsed the CONSORT Statement or
the URM in their instructions for authors are assumed as follows.
First, most medical schools, hospitals or medical research institutes
in China required their fellows to publish their papers in the core
journals to facilitate their promotion or graduation, but with a lack
of attention paid to who conducted what aspects of the study.
Within such a bureaucratic system, the focus is on quick success
and instant benefits. On the other hand, core medical journals are
in large quantities and the good and the bad are intermingled. So
if one journal enhances the threshold for its acceptance of
manuscripts, it would lose most authors and obtain little benefit.
After all, not all journals in China have the need to be adhering to
international conventions. Second, Chinese authors who conduct-
ed high-quality clinical research, would prefer to publish their
Table 1. RCT reports from 6 Chinese medical journals endorsing the CONSORT Statement.
Journal title
Publication







Chinese Journal of Cancer Biotherapy Bimonthly June 2010 to June 2011 2 0 0
Chinese Journal of Evidence-Based Medicine Monthly June 2010 to June 2011 5 1 0
Chinese Journal of Evidence-based Pediatrics Bimonthly June 2010 to June 2011 3 1 0
Chinese Medical Journal (English version) Semimonthly January 2011 to June 2011 23 5 3
Journal of Chinese Integrative Medicine Monthly June 2010 to June 2011 10 10 0
Journal of Clinical Rehabilitative
Tissue Engineering Research
Weekly January 2011 to June 2011 19 3 0
Total — — 62 20 3
RCT: randomised controlled trial.
doi:10.1371/journal.pone.0030683.t001
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journals. As a result, the low-quality journals and the low-quality
manuscripts have created a chicken-and-egg problem in China. So
even for some international journals in China such as those
endorseing the CONSORT Statement, the URM, or trial
registration in their instructions for authors, they would not tend
to stress these requirements to their authors. This explained why
we found that most of the six journals endorsing the CONSORT
Statement failed to adhere to the standards by reviewing their
published RCTs.
This work has some limitations. First, this study used the
electronic resources which may change during the study period.
However, at the end of the study, no journals updated their
instructions for authors. Second, no telephone calls were made and
no emails were sent to the editorial offices of the journals
investigated as per the study by Hopewell et al [8]. Therefore, we
do not know the opinions of the journal editors about the issue
concerned in this study. However, having reviewed the published
papers in these journals, it could be estimated that their responses
would not be positive. Third, some Chinese medical journals that
are indexed in the SCI but not in the CSTJCR due to few citations
by Chinese journals were not included in this study. The number
of such journals is very small so we may assume that the results
would not be affected.
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